153 related articles for article (PubMed ID: 10546792)
21. High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma.
Bloor AJ; Thomson K; Chowdhry N; Verfuerth S; Ings SJ; Chakraverty R; Linch DC; Goldstone AH; Peggs KS; Mackinnon S
Biol Blood Marrow Transplant; 2008 Jan; 14(1):50-8. PubMed ID: 18158961
[TBL] [Abstract][Full Text] [Related]
22. Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation.
Mandigers CM; Verdonck LF; Meijerink JP; Dekker AW; Schattenberg AV; Raemaekers JM
Bone Marrow Transplant; 2003 Dec; 32(12):1159-63. PubMed ID: 14647270
[TBL] [Abstract][Full Text] [Related]
23. Autologous bone marrow versus non-mobilized peripheral blood stem cell transplantation for lymphoid malignancies: a prospective, comparative trial.
Weisdorf DJ; Verfaille CM; Miller WJ; Blazar BR; Perry E; Shu XO; Daniels K; Hannan P; Ramsay NK; Kersey JH; McGlave PB
Am J Hematol; 1997 Mar; 54(3):202-8. PubMed ID: 9067498
[TBL] [Abstract][Full Text] [Related]
24. Outcomes of autologous or allogeneic stem cell transplantation for non-Hodgkin lymphoma.
Reddy NM; Oluwole O; Greer JP; Engelhardt BG; Jagasia MH; Savani BN
Exp Hematol; 2014 Jan; 42(1):39-45. PubMed ID: 24096123
[TBL] [Abstract][Full Text] [Related]
25. Tandem autologous-allo-SCT is feasible in patients with high-risk relapsed non-Hodgkin's lymphoma.
Crocchiolo R; Castagna L; Fürst S; El-Cheikh J; Faucher C; Oudin C; Granata A; Bouabdallah R; Coso D; Chabannon C; Balzarotti M; Santoro A; Blaise D
Bone Marrow Transplant; 2013 Feb; 48(2):249-52. PubMed ID: 22732704
[TBL] [Abstract][Full Text] [Related]
26. Autologous transplantation for relapsed non-Hodgkin's lymphoma using intravenous busulfan and cyclophosphamide as conditioning regimen: a single center experience.
Escalón MP; Stefanovic A; Venkatraman A; Pereira D; Santos ES; Goodman M; Byrnes JJ; Fernandez HF
Bone Marrow Transplant; 2009 Jul; 44(2):89-96. PubMed ID: 19169287
[TBL] [Abstract][Full Text] [Related]
27. [Comparison of the effectiveness of hematopoietic cell mobilization with chemotherapy and filgrastim versus filgrastim alone for autologous transplant in patients with lymphoma.].
Gutiérrez-Aguirre CH; De la Garza-Salazar F; Cantú-Rodríguez O; González-Llano Ó; Jaime-Pérez JC; Mancias-Guerra C; García-Sepúlveda R; Salazar-Riojas R; Gómez-Almaguer D
Gac Med Mex; 2016 Oct; 152(Suppl 2):57-65. PubMed ID: 27792717
[TBL] [Abstract][Full Text] [Related]
28. Stem cell transplantation for non-Hodgkin's lymphoma.
Wrench D; Gribben JG
Hematol Oncol Clin North Am; 2008 Oct; 22(5):1051-79, xi. PubMed ID: 18954751
[TBL] [Abstract][Full Text] [Related]
29. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma.
Carella AM; Cavaliere M; Lerma E; Ferrara R; Tedeschi L; Romanelli A; Vinci M; Pinotti G; Lambelet P; Loni C; Verdiani S; De Stefano F; Valbonesi M; Corsetti MT
J Clin Oncol; 2000 Dec; 18(23):3918-24. PubMed ID: 11099321
[TBL] [Abstract][Full Text] [Related]
30. Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV).
Wheeler C; Khurshid A; Ibrahim J; Elias A; Mauch P; Ault K; Antin J
Leuk Lymphoma; 2001 Feb; 40(5-6):499-509. PubMed ID: 11426523
[TBL] [Abstract][Full Text] [Related]
31. No polarization of type 1 or type 2 precursor dendritic cells in peripheral blood stem cell collections of non-hodgkin's lymphoma patients mobilized with cyclophosphamide plus G-CSF, GM-CSF, or GM-CSF followed by G-CSF.
Gazitt Y; Akay C; Thomas C
Stem Cells Dev; 2006 Apr; 15(2):269-77. PubMed ID: 16646673
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of comorbidity for auto-SCT eligibility and outcome in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Plattel WJ; Kluin-Nelemans HC; de Bock GH; van Imhoff GW
Bone Marrow Transplant; 2011 Jun; 46(6):827-34. PubMed ID: 20729926
[TBL] [Abstract][Full Text] [Related]
33. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation.
Peniket AJ; Ruiz de Elvira MC; Taghipour G; Cordonnier C; Gluckman E; de Witte T; Santini G; Blaise D; Greinix H; Ferrant A; Cornelissen J; Schmitz N; Goldstone AH;
Bone Marrow Transplant; 2003 Apr; 31(8):667-78. PubMed ID: 12692607
[TBL] [Abstract][Full Text] [Related]
34. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells.
van Besien K; Margolin K; Champlin R; Forman S
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S54-8. PubMed ID: 9457395
[TBL] [Abstract][Full Text] [Related]
35. Favorable outcomes from allogeneic and autologous stem cell transplantation for patients with transformed nonfollicular indolent lymphoma.
Villa D; George A; Seymour JF; Toze CL; Crump M; Lee C; Buckstein R; Stewart DA; MacDonald D; Foley R; Xenocostas A; Sabloff M; Chua N; Couture F; Larouche JF; Cohen S; Savage KJ; Connors JM; Panzarella T; Carney DA; Dickinson M; Kuruvilla J
Biol Blood Marrow Transplant; 2014 Nov; 20(11):1813-8. PubMed ID: 25042735
[TBL] [Abstract][Full Text] [Related]
36. Long-term results of autologous stem cell transplantation for Hodgkin's disease (HD) and low-/intermediate-grade B non-Hodgkin's lymphoma (NHL): a report from the Austrian Stem Cell Transplantation Registry (ASCTR).
Nachbaur D; Greinix HT; Koller E; Krieger O; Linkesch W; Kasparu H; Pober M; Hinterberger W; Hausmaninger H; Heistinger M; Ulsperger E; Karlhuber S; Schwinger W; Lindner B
Ann Hematol; 2005 Jul; 84(7):462-73. PubMed ID: 15726362
[TBL] [Abstract][Full Text] [Related]
37. Long-term follow-up of patients with non-Hodgkin lymphoma following myeloablative therapy and autologous transplantation of CD34+-selected peripheral blood progenitor cells.
Witzens-Harig M; Heilmann C; Hensel M; Kornacker M; Benner A; Haas R; Fruehauf S; Ho AD
Stem Cells; 2007 Jan; 25(1):228-35. PubMed ID: 17204607
[TBL] [Abstract][Full Text] [Related]
38. Peripheral-blood stem-cell transplantation versus autologous bone marrow transplantation in Hodgkin's and non-Hodgkin's lymphomas: a new matched-pair analysis of the European Group for Blood and Marrow Transplantation Registry Data. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
Majolino I; Pearce R; Taghipour G; Goldstone AH
J Clin Oncol; 1997 Feb; 15(2):509-17. PubMed ID: 9053472
[TBL] [Abstract][Full Text] [Related]
39. Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma.
Buckstein R; Imrie K; Spaner D; Potichnyj A; Robinson JB; Nanji S; Pennel N; Reis M; Pinkerton P; Dubé I; Hewitt K; Berinstein NL
Semin Oncol; 1999 Oct; 26(5 Suppl 14):115-22. PubMed ID: 10561026
[TBL] [Abstract][Full Text] [Related]
40. [Allogeneic transplantation in malignant lymphoma].
Stötzer OJ; Schleuning M; Ledderose G; Hiddemann W; Kolb HJ
Dtsch Med Wochenschr; 2001 Sep; 126(39):1062-9. PubMed ID: 11602913
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
